These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 2884415)

  • 1. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
    Kontoghiorghes GJ; Aldouri MA; Sheppard L; Hoffbrand AV
    Lancet; 1987 Jun; 1(8545):1294-5. PubMed ID: 2884415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
    Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose response studies using desferrioxamine and orally active chelators in a mouse model.
    Kontoghiorghes GJ
    Scand J Haematol; 1986 Jul; 37(1):63-70. PubMed ID: 3764334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
    al-Refaie FN; Wonke B; Wickens DG; Aydinok Y; Fielding A; Hoffbrand AV
    J Clin Pathol; 1994 Jul; 47(7):657-60. PubMed ID: 8089225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of iron overload states with oral administration of the chelator agent, L1 (Deferiprone)].
    Cermák J; Brabec V
    Vnitr Lek; 1994 Sep; 40(9):586-90. PubMed ID: 7975362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
    Collins AF; Fassos FF; Stobie S; Lewis N; Shaw D; Fry M; Templeton DM; McClelland RA; Koren G; Olivieri NF
    Blood; 1994 Apr; 83(8):2329-33. PubMed ID: 8161801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
    Kontoghiorghes GJ
    Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
    Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D
    Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
    Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
    Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
    Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV; Goddard JG; Sheppard L; Barr J; Nortey P
    Br J Haematol; 1990 Oct; 76(2):295-300. PubMed ID: 2094333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
    Olivieri NF; Koren G; Hermann C; Bentur Y; Chung D; Klein J; St Louis P; Freedman MH; McClelland RA; Templeton DM
    Lancet; 1990 Nov; 336(8726):1275-9. PubMed ID: 1978115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally active iron chelators.
    Merson L; Olivier N
    Blood Rev; 2002 Jun; 16(2):127-34. PubMed ID: 12127956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans.
    Thuma PE; Olivieri NF; Mabeza GF; Biemba G; Parry D; Zulu S; Fassos FF; McClelland RA; Koren G; Brittenham GM; Gordeuk VR
    Am J Trop Med Hyg; 1998 Mar; 58(3):358-64. PubMed ID: 9546419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig.
    Wong A; Alder V; Robertson D; Papadimitriou J; Maserei J; Berdoukas V; Kontoghiorghes G; Taylor E; Baker E
    Biometals; 1997 Oct; 10(4):247-56. PubMed ID: 9353871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
    Kontoghiorghes GJ; Bartlett AN; Sheppard L; Barr J; Nortey P
    Arzneimittelforschung; 1995 Jan; 45(1):65-9. PubMed ID: 7893273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.
    Kontoghiorghes GJ; Hoffbrand AV
    Br J Haematol; 1986 Apr; 62(4):607-13. PubMed ID: 3964556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral iron-chelating therapy: the L1 experience.
    al-Refaie FN; Hoffbrand AV
    Baillieres Clin Haematol; 1994 Dec; 7(4):941-63. PubMed ID: 7881161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
    Wong CS; Kwok JC; Richardson DR
    Biochim Biophys Acta; 2004 Dec; 1739(1):70-80. PubMed ID: 15607119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.